Core Points - The company held its second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any rejections [2][4][8] Meeting Details - The meeting was convened by the board of directors and chaired by Dr. Xuefeng Yu, utilizing a combination of on-site and online voting methods, complying with relevant laws and regulations [2][3] - All seven current directors and three supervisors attended the meeting, along with the board secretary and other executives [3] Resolutions Passed - The following key resolutions were approved: - Cancellation of the supervisory board and amendments to the Articles of Association [4] - Approval of the rules for shareholder meetings and board meetings [4][5] - Revision of various corporate governance systems, including fundraising management, related party transaction management, external guarantee decision-making, external investment management, and independent non-executive director work systems [5] - Use of surplus reserves to offset losses, with a total of CNY 1,450,342,128.90 allocated from surplus reserves and capital reserves [5][9] Legal Compliance - The meeting was witnessed by lawyers from Beijing Jingtian & Gongcheng Law Firm, confirming that the meeting's procedures and voting results were legally valid [7] Notification to Creditors - The company announced its intention to use capital reserves to offset losses and informed creditors of their rights to claim debts within specified timeframes [11][12]
康希诺生物股份公司2025年第二次临时股东大会决议公告